Webinar: Process Impurities: Don’t Let PEI or HCP Derail Your Biotherapy
September 12, 2019 - Rockville MD US
The manufacturing of a biotherapy involves multiple inputs, ranging in complexity from a transfection reagent to the host cell in which the therapy is manufactured. All of these process components should be removed prior to the therapy being available for human use. During this webinar we will review strategies within product characterization to de-risk the manufacturing process for cell and gene therapies and monoclonal antibodies (mAbs). We will focus on how we effectively detect and characterize polyethylenimine (PEI), used in cell and gene therapy products and host cell proteins, a factor in mAb therapies and cell and gene therapies.